Lyell Immunopharma Inc (LYEL) FinancialsLYELFinancialLyell Immunopharma Inc

Evaluating the bottom line, Lyell Immunopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1183425.00%, while the net margin is -1118875.00%. These profitability ratios, combined with a Return on Equity (ROE) of -93.28%, provide a clear picture of how effectively LYEL converts its operational activities into shareholder value.

In the context of the broader market, LYEL competes directly with industry leaders such as FHTX and ZNTL. With a market capitalization of $341.85M, it holds a significant position in the sector. When comparing efficiency, LYEL's gross margin of 100.00% stands against FHTX's 100.00% and ZNTL's N/A. Such benchmarking helps identify whether Lyell Immunopharma, Inc. is trading at a premium or discount relative to its financial performance.

Lyell Immunopharma has shown a gross margin of 100% consistently, indicating strong revenue generation relative to costs, although it has been facing significant net losses.